EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors

David König, Heinz Läubli

Pharmacology · 2021 · 106 (3-4) · 123-136

DOI: 10.1159/000509081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacology, online erschienen am 28.07.2020. Verfasst von David König und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have changed the prognosis of many cancer patients. Blocking antibodies targeting inhibitory cytotoxic T-lymphocyte-associated antigen 4 or programmed cell death protein-1 receptors or the programmed cell death ligand-1 have led to long-lasting remissions in patients with even advanced cancers. Main side effects induced by ICIs are inflammatory complications with sometimes severe sequelae for patients. Recent studies have improved our understanding how such immune-related adverse events (irAEs) develop. Here, we summarize the current knowledge of pathomechanisms involved in the de­velopment of irAEs with a particular focus on potential pathways that could be targeted to prevent severe immune-related complications in patients treated with cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, PharmacologicalCTLA-4 AntigenDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

AntibodyAutoimmuneB cellCross-presentationCytokineCytotoxic T-lymphocyte-associated antigen 4Programmed cell death protein-1T cell

Substanzen

Biomarkers, PharmacologicalCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Division of Medical Oncology, University Hospital Basel, Basel, Switzerland, heinz.laeubli@unibas.ch.
  • Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Basel, Switzerland, heinz.laeubli@unibas.ch.

Zitieren

APA

König, D., & Läubli, H. (2021). Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology, 106(3-4), 123-136. https://doi.org/10.1159/000509081

Vancouver

König D, Läubli H. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology. 2021;106(3-4):123-136. doi:10.1159/000509081

BibTeX
@article{Knig2021,
  author = {König, David and Läubli, Heinz},
  title = {Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors},
  journal = {Pharmacology},
  year = {2021},
  volume = {106},
  number = {3-4},
  pages = {123--136},
  doi = {10.1159/000509081}
}
Kostenlos starten →